Predictors of survival in immunotherapy-based treatments in advanced melanoma: a meta-analysis.
Daishi LiYuming SunJiayuan LeYating DianYihuang LiuFurong ZengGuang-Tong DengShaorong LeiJuan SuPublished in: International journal of dermatology (2024)
The introduction of immunotherapy-based strategies has significantly improved the prognosis for melanoma patients. Nevertheless, some patients still have dismal outcomes, emphasizing the significance of survival predictive indicators in immunotherapy-based approaches. We systematically searched randomized controlled clinical trials investigating dual immunotherapy or chemoimmunotherapy versus placebo or mono-immunotherapy or chemotherapy alone in advanced melanoma patients. R version 4.3.0. was employed to perform all analyses. A comprehensive analysis was conducted on a total of 13,809 patients with advanced melanoma from 19 randomized clinical trials. Immunotherapy-based strategies (alone or in combination) could significantly lengthen the overall survival(OS) and recurrence-free survival (RFS) compared with corresponding controls. Mono-immunotherapy improved RFS and OS in PD-L1 positive patients, in stage AJCC IIIC, and with 4 or more positive lymph nodes, compared with chemotherapy. Combined immunotherapy statistically improved RFS and OS in those aged < 65, with an Eastern Cooperative Oncology Group (ECOG) status of 0, and LDH ≤ ULN at baseline compared with single treatment alone. Our findings indicated that certain clinicopathological and molecular features could assist in choosing appropriate melanoma patients for immune-based treatments.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- clinical trial
- free survival
- chronic kidney disease
- peritoneal dialysis
- lymph node
- prognostic factors
- type diabetes
- randomized controlled trial
- adipose tissue
- patient reported outcomes
- metabolic syndrome
- weight loss
- radiation therapy
- single molecule
- chemotherapy induced
- glycemic control
- phase ii